Intravitreal topotecan

DRUG2 trials

Sponsors

Unity Health Toronto

Conditions

Proliferative VitreoretinopathyProliferative Vitreoretinopathy in Rhegmatogenous Retinal DetachmentRetinal Detachment Rhegmatogenous

Phase 2

Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy

RecruitingNCT05523869

Unity Health TorontoProliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Start: 2023-02-23End: 2026-02-28Target: 50Updated: 2025-02-11

Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

Not yet recruitingNCT06818721

Unity Health TorontoProliferative Vitreoretinopathy, Retinal Detachment Rhegmatogenous

Start: 2025-03-31End: 2027-04-30Target: 394Updated: 2025-03-06